The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the shifting strategic priorities of global retail giants, negotiations are underway to sell the Boots pharmacy chain in a deal that could be valued at $10 billion. According to reports, this potential sale could lead the company to abandon its long-discussed plans for a public listing on the London Stock Exchange. The parent company, Walgreens Boots Alliance, is currently weighing strategic alternatives for the UK-based chain, balancing a direct divestment against a public market debut.
Sign in to access this content
Sign InThe shift toward a private sale comes as the London market struggles to retain high-profile IPOs. The retail environment in the UK has shown signs of resilience; per market data from the BRC Retail Sales Monitor on June 8, 2026, annual retail sales grew by 3.4%, significantly outperforming the 0.6% forecast. This improved consumer backdrop likely supports the $10 billion valuation target, which sits higher than the reported £7 billion price tag discussed during a failed sale attempt in 2022.
Market participants are now watching for formal confirmation of the bidding parties and the final structure of the deal. With UK retail sales showing unexpected strength in early June, the timing may be optimal for a clean exit. Investors should monitor upcoming corporate filings from Walgreens Boots Alliance for definitive guidance on whether the London IPO remains a viable secondary option or if a private equity consortium will take the lead.